BioSpace News Archive

The findings from Finerenone’s study were presented at the virtual American Society of Nephrology’s (ASN) Kidney Week 2020 on October 23, and the full study was published in a recent online edition of the New England Journal of Medicine.

Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which it currently holds an approximately one-third equity stake) and has supported Medicago’s innovative plant-derived research and development focused on vaccines.

Precision Nanosystems, Inc. (PNI), a global leader in technologies and solutions in genetic medicine, announced today that it has received a commitment of up to $18.2 million in support from the Government of Canada under the Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to develop a COVID-19 vaccine.

Precision Nanosystems, Inc. (PNI), a global leader in technologies and solutions in genetic medicine, announced today that it has received a commitment of up to $18.2 million in support from the Government of Canada under the Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to develop a COVID-19 vaccine

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, announced new hire grants totaling an aggregate of 58,800 inducement restricted stock awards to eleven employees.

LSO remains concerned by today’s release of the final PMPRB guidelines implementing the federal government’s patented medicine price controls. The final guidelines create a highly risky and uncertain pathway for commercializing new medicines and vaccines in Canada. LSO President and CEO Jason Field wants to ask the Government of Canada “why did it take four months for the PMPRB to publish guidelines that contain no sub

Detection of genomic alterations that drive the growth and spread of the tumor can guide treatment decisions for cancer therapies, including available biomarker driven treatments FoundationOne ® CDx analyzes substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes as well as select rearrangements and genomic signatures across all solid tumors, including the three NTRK gene fusions ( NTRK 1, NTRK 2

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed a private placement (the “Offering”) to certain investors in the United States of U.S.$532,000 principal amount of 8% convertible notes due October 15, 2024 (the “Notes”).

Advanced Reimbursement Solutions LLC (ARS), a Scottsdale-based medical billing and revenue cycle management enterprise, challenged Blue Cross Blue Shield of Arizona (BCBS of AZ) for its approval and subsequent denial of a double-mastectomy patient.

Akumin Inc. (NASDAQ: AKU) (TSX: AKU) (the “Issuer”), announced today that it priced a private offering (the “Private Offering”) of $400 million of aggregate principal amount of 7.00% senior secured notes due 2025 (the “Notes”). The offering of the Notes is scheduled to close on November 2, 2020 , s